Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
73
TEVJF Quote, Financials, Valuation and Earnings
Last price:
$28.61
Seasonality move
:
5.37%
Day range:
$28.61 - $28.61
52-week range:
$13.73 - $28.61
Dividend yield:
0%
P/E ratio:
47.06x
P/S ratio:
1.97x
P/B ratio:
4.53x
Volume:
--
Avg. volume:
8
1-year change:
41.02%
Market cap:
$32.8B
Revenue:
$16.5B
EPS (TTM):
$0.61
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TEVJF
Teva Pharmaceutical Industries Ltd.
|
$4.3B | -- | 4.33% | -- | -- |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -3.23% | -72.97% | $3.25 |
|
CGEN
Compugen Ltd.
|
$1.5M | -$0.09 | -7.77% | -9.81% | $6.25 |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | -- |
|
PHGE
BiomX, Inc.
|
-- | -$6.08 | -- | -206.85% | $399.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TEVJF
Teva Pharmaceutical Industries Ltd.
|
$28.61 | -- | $32.8B | 47.06x | $0.00 | 0% | 1.97x |
|
CANF
Can-Fite BioPharma Ltd.
|
$0.24 | $3.25 | $3.8M | -- | $0.00 | 0% | 1.36x |
|
CGEN
Compugen Ltd.
|
$1.53 | $6.25 | $142.6M | 55.83x | $0.00 | 0% | 20.37x |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
PHGE
BiomX, Inc.
|
$2.07 | $399.00 | $3.2M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TEVJF
Teva Pharmaceutical Industries Ltd.
|
70.19% | 1.456 | 74.36% | 0.53x |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | 0.899 | -- | -- |
|
CGEN
Compugen Ltd.
|
6.3% | 2.845 | 2.14% | 4.24x |
|
NSRX
Nasus Pharma
|
-- | 0.000 | -- | -- |
|
PHGE
BiomX, Inc.
|
38.57% | 0.072 | 20.14% | 1.51x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TEVJF
Teva Pharmaceutical Industries Ltd.
|
$2.3B | $1.1B | 2.72% | 10.18% | 23.84% | $552.9M |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -- | -- | -- | -- |
|
CGEN
Compugen Ltd.
|
$241K | -$7.9M | -49.12% | -51.8% | -417.4% | -- |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | -- | -- |
|
PHGE
BiomX, Inc.
|
-$1.2M | -$8.5M | -116.24% | -160.84% | -- | -$7.2M |
Teva Pharmaceutical Industries Ltd. vs. Competitors
-
Which has Higher Returns TEVJF or CANF?
Can-Fite BioPharma Ltd. has a net margin of 9.71% compared to Teva Pharmaceutical Industries Ltd.'s net margin of --. Teva Pharmaceutical Industries Ltd.'s return on equity of 10.18% beat Can-Fite BioPharma Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TEVJFTeva Pharmaceutical Industries Ltd.51.33% $0.37 $24.3B CANFCan-Fite BioPharma Ltd.-- -- -- -
What do Analysts Say About TEVJF or CANF?
Teva Pharmaceutical Industries Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Can-Fite BioPharma Ltd. has an analysts' consensus of $3.25 which suggests that it could grow by 1228.16%. Given that Can-Fite BioPharma Ltd. has higher upside potential than Teva Pharmaceutical Industries Ltd., analysts believe Can-Fite BioPharma Ltd. is more attractive than Teva Pharmaceutical Industries Ltd..
Company Buy Ratings Hold Ratings Sell Ratings TEVJFTeva Pharmaceutical Industries Ltd.0 0 0 CANFCan-Fite BioPharma Ltd.2 0 0 -
Is TEVJF or CANF More Risky?
Teva Pharmaceutical Industries Ltd. has a beta of 0.694, which suggesting that the stock is 30.584% less volatile than S&P 500. In comparison Can-Fite BioPharma Ltd. has a beta of 0.982, suggesting its less volatile than the S&P 500 by 1.756%.
-
Which is a Better Dividend Stock TEVJF or CANF?
Teva Pharmaceutical Industries Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Can-Fite BioPharma Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teva Pharmaceutical Industries Ltd. pays -- of its earnings as a dividend. Can-Fite BioPharma Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TEVJF or CANF?
Teva Pharmaceutical Industries Ltd. quarterly revenues are $4.5B, which are larger than Can-Fite BioPharma Ltd. quarterly revenues of --. Teva Pharmaceutical Industries Ltd.'s net income of $434M is higher than Can-Fite BioPharma Ltd.'s net income of --. Notably, Teva Pharmaceutical Industries Ltd.'s price-to-earnings ratio is 47.06x while Can-Fite BioPharma Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teva Pharmaceutical Industries Ltd. is 1.97x versus 1.36x for Can-Fite BioPharma Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TEVJFTeva Pharmaceutical Industries Ltd.1.97x 47.06x $4.5B $434M CANFCan-Fite BioPharma Ltd.1.36x -- -- --
-
Which has Higher Returns TEVJF or CGEN?
Compugen Ltd. has a net margin of 9.71% compared to Teva Pharmaceutical Industries Ltd.'s net margin of -369.06%. Teva Pharmaceutical Industries Ltd.'s return on equity of 10.18% beat Compugen Ltd.'s return on equity of -51.8%.
Company Gross Margin Earnings Per Share Invested Capital TEVJFTeva Pharmaceutical Industries Ltd.51.33% $0.37 $24.3B CGENCompugen Ltd.12.75% -$0.07 $46.8M -
What do Analysts Say About TEVJF or CGEN?
Teva Pharmaceutical Industries Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Compugen Ltd. has an analysts' consensus of $6.25 which suggests that it could grow by 308.5%. Given that Compugen Ltd. has higher upside potential than Teva Pharmaceutical Industries Ltd., analysts believe Compugen Ltd. is more attractive than Teva Pharmaceutical Industries Ltd..
Company Buy Ratings Hold Ratings Sell Ratings TEVJFTeva Pharmaceutical Industries Ltd.0 0 0 CGENCompugen Ltd.4 0 0 -
Is TEVJF or CGEN More Risky?
Teva Pharmaceutical Industries Ltd. has a beta of 0.694, which suggesting that the stock is 30.584% less volatile than S&P 500. In comparison Compugen Ltd. has a beta of 2.818, suggesting its more volatile than the S&P 500 by 181.823%.
-
Which is a Better Dividend Stock TEVJF or CGEN?
Teva Pharmaceutical Industries Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teva Pharmaceutical Industries Ltd. pays -- of its earnings as a dividend. Compugen Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TEVJF or CGEN?
Teva Pharmaceutical Industries Ltd. quarterly revenues are $4.5B, which are larger than Compugen Ltd. quarterly revenues of $1.9M. Teva Pharmaceutical Industries Ltd.'s net income of $434M is higher than Compugen Ltd.'s net income of -$7M. Notably, Teva Pharmaceutical Industries Ltd.'s price-to-earnings ratio is 47.06x while Compugen Ltd.'s PE ratio is 55.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teva Pharmaceutical Industries Ltd. is 1.97x versus 20.37x for Compugen Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TEVJFTeva Pharmaceutical Industries Ltd.1.97x 47.06x $4.5B $434M CGENCompugen Ltd.20.37x 55.83x $1.9M -$7M
-
Which has Higher Returns TEVJF or NSRX?
Nasus Pharma has a net margin of 9.71% compared to Teva Pharmaceutical Industries Ltd.'s net margin of --. Teva Pharmaceutical Industries Ltd.'s return on equity of 10.18% beat Nasus Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TEVJFTeva Pharmaceutical Industries Ltd.51.33% $0.37 $24.3B NSRXNasus Pharma-- -- -- -
What do Analysts Say About TEVJF or NSRX?
Teva Pharmaceutical Industries Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Nasus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Teva Pharmaceutical Industries Ltd. has higher upside potential than Nasus Pharma, analysts believe Teva Pharmaceutical Industries Ltd. is more attractive than Nasus Pharma.
Company Buy Ratings Hold Ratings Sell Ratings TEVJFTeva Pharmaceutical Industries Ltd.0 0 0 NSRXNasus Pharma0 0 0 -
Is TEVJF or NSRX More Risky?
Teva Pharmaceutical Industries Ltd. has a beta of 0.694, which suggesting that the stock is 30.584% less volatile than S&P 500. In comparison Nasus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock TEVJF or NSRX?
Teva Pharmaceutical Industries Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nasus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teva Pharmaceutical Industries Ltd. pays -- of its earnings as a dividend. Nasus Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TEVJF or NSRX?
Teva Pharmaceutical Industries Ltd. quarterly revenues are $4.5B, which are larger than Nasus Pharma quarterly revenues of --. Teva Pharmaceutical Industries Ltd.'s net income of $434M is higher than Nasus Pharma's net income of --. Notably, Teva Pharmaceutical Industries Ltd.'s price-to-earnings ratio is 47.06x while Nasus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teva Pharmaceutical Industries Ltd. is 1.97x versus -- for Nasus Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TEVJFTeva Pharmaceutical Industries Ltd.1.97x 47.06x $4.5B $434M NSRXNasus Pharma-- -- -- --
-
Which has Higher Returns TEVJF or PHGE?
BiomX, Inc. has a net margin of 9.71% compared to Teva Pharmaceutical Industries Ltd.'s net margin of --. Teva Pharmaceutical Industries Ltd.'s return on equity of 10.18% beat BiomX, Inc.'s return on equity of -160.84%.
Company Gross Margin Earnings Per Share Invested Capital TEVJFTeva Pharmaceutical Industries Ltd.51.33% $0.37 $24.3B PHGEBiomX, Inc.-- -$5.55 $17.1M -
What do Analysts Say About TEVJF or PHGE?
Teva Pharmaceutical Industries Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand BiomX, Inc. has an analysts' consensus of $399.00 which suggests that it could grow by 19175.36%. Given that BiomX, Inc. has higher upside potential than Teva Pharmaceutical Industries Ltd., analysts believe BiomX, Inc. is more attractive than Teva Pharmaceutical Industries Ltd..
Company Buy Ratings Hold Ratings Sell Ratings TEVJFTeva Pharmaceutical Industries Ltd.0 0 0 PHGEBiomX, Inc.1 0 0 -
Is TEVJF or PHGE More Risky?
Teva Pharmaceutical Industries Ltd. has a beta of 0.694, which suggesting that the stock is 30.584% less volatile than S&P 500. In comparison BiomX, Inc. has a beta of 1.558, suggesting its more volatile than the S&P 500 by 55.818%.
-
Which is a Better Dividend Stock TEVJF or PHGE?
Teva Pharmaceutical Industries Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BiomX, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teva Pharmaceutical Industries Ltd. pays -- of its earnings as a dividend. BiomX, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TEVJF or PHGE?
Teva Pharmaceutical Industries Ltd. quarterly revenues are $4.5B, which are larger than BiomX, Inc. quarterly revenues of --. Teva Pharmaceutical Industries Ltd.'s net income of $434M is higher than BiomX, Inc.'s net income of -$9.2M. Notably, Teva Pharmaceutical Industries Ltd.'s price-to-earnings ratio is 47.06x while BiomX, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teva Pharmaceutical Industries Ltd. is 1.97x versus -- for BiomX, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TEVJFTeva Pharmaceutical Industries Ltd.1.97x 47.06x $4.5B $434M PHGEBiomX, Inc.-- -- -- -$9.2M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 24
Applied Optoelectronics, Inc. [AAOI] is up 4.16% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.99% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 3.04% over the past day.
